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Two different approaches to analysis of data from diagnostic
biomarker studies are commonly employed. Logistic regression is used
to fit models for probability of disease given marker values, while
ROC curves and risk distributions are used to evaluate classification
performance. In this paper we present a method that simultaneously
accomplishes both tasks. The key step is to standardize markers rela-
tive to the nondiseased population before including them in the logis-
tic regression model. Among the advantages of this method are the
following: (i) ensuring that results from regression and performance
assessments are consistent with each other; (ii) allowing covariate
adjustment and covariate effects on ROC curves to be handled in
a familiar way, and (iii) providing a mechanism to incorporate im-
portant assumptions about structure in the ROC curve into the fit-
ted risk model. We develop the method in detail for the problem of
combining biomarker data sets derived from multiple studies, popu-
lations or biomarker measurement platforms, when ROC curves are
similar across data sources. The methods are applicable to both co-
hort and case–control sampling designs. The data set motivating this
application concerns Prostate Cancer Antigen 3 (PCA3) for diagno-
sis of prostate cancer in patients with or without previous negative
biopsy where the ROC curves for PCA3 are found to be the same in
the two populations. The estimated constrained maximum likelihood
and empirical likelihood estimators are derived. The estimators are
compared in simulation studies and the methods are illustrated with
the PCA3 data set.
1. Introduction. As myriads of biomarkers are becoming available from
research laboratories, the demand for more sophisticated statistical analysis
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methods increases. For example, an emerging request is to combine infor-
mation from multiple sources in evaluating a biomarker’s performance. In
addition, biomarkers must be evaluated from multiple points of view, includ-
ing, for example, their roles as risk factors and predictors as well as their
classification performance.
Logistic regression analysis has been a mainstay of biostatistical method-
ology for evaluating risk factors, particularly in epidemiology and in ther-
apeutic research. For evaluating biomarker performance, however, other
methods are more appropriate, such as those based on receiver operating
characteristic (ROC) curves [Pepe (2003)] and risk distributions. Methods
that evaluate categorized risk distributions are gaining popularity and are
often called risk reclassification methods. However, in general, methods for
evaluating performance are far less well developed and have more limited
availability than logistic regression methodology.
In this paper we show that evaluation of biomarker performance can be
achieved within the logistic regression framework if as a preliminary step
one standardizes the marker using the control population to define the ref-
erence distribution for standardization. Previously, in a simple setting with
the biomarker as the only predictor of interest, Gu and Pepe (2010) ap-
plied a logistic regression model to standardized marker values as a rank-
invariant approach to estimating the variance of the empirical ROC curve
in sample size calculations. Here we extend the approach to estimate the
ROC curve itself and to allow for additional covariates. Through recogni-
tion of the fact that there is a direct functional relationship between the
coefficient for the standardized marker in the logistic regression model and
the ROC curve, we show that risk distributions as well as the ROC curve
conditional on covariates can be calculated directly from coefficients in the
model and that incorporating this relationship into estimation leads to ef-
ficiency gains. Since the method simultaneously evaluates the marker as a
risk factor and the marker’s performance as a classifier, it provides a more
coherent approach than current methods that separately evaluate the two
aspects. Potentially inconsistent results are avoided. The framework has sev-
eral other attributes. First, estimated ROC curves can be constrained to be
concave if desired. Concavity is a fundamental property of the ROC curve
that is not taken advantage of by most standard methods. Second, covari-
ate effects on biomarker performance can be addressed naturally within the
logistic regression framework. Third, the method is rank invariant with re-
spect to the marker, adding a degree of robustness compared with usual
logistic regression.
The general framework and methods for estimation are presented in Sec-
tion 2. The method is then developed in some detail for the problem of
evaluating a biomarker using data derived from multiple studies or popula-
tions when a common ROC curve across data sources is of interest. This is
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an important problem for which methodology has not been proposed hereto-
fore. Consider that prior to launching a large validation study, data from
multiple small studies, possibly using different assay platforms, may be ex-
amined. Methods that can combine information across studies are needed
in this setting. Moreover, when a large collaborative validation study is un-
dertaken, it typically involves multiple sites that may each follow somewhat
different protocols or involve multiple subpopulations that differ in regard
to patient characteristics. Again, in this setting, our methods for combin-
ing data based on a common ROC curve will be useful. The example that
motivated our work concerns evaluating a prostate cancer biomarker in two
subpopulations of men.
In Section 3 we describe this example in detail and develop three methods
for estimating parameters in the logistic regression model. We evaluate the
properties of these estimators in simulation studies and describe results in
Section 4. In Section 5 we illustrate the methodology using the data set
from the prostate cancer biomarker study and finish with some concluding
remarks in Section 6.
2. The general framework: Logistic regression applied to standardized
biomarker values.
2.1. The risk model is related to the ROC curve. Consider a binary out-
come D, disease, say, with D = 0 for control nondiseased subjects and D = 1
for case diseased subjects, a single continuous marker Y , and additional co-
variates denoted by X . Note the marker Y may be a predefined combination
of predictors. For example, the Framingham risk score is a linear combina-
tion of risk factors for cardiovascular events including age, total cholesterol,
and systolic blood pressure. Another example is the Oncotype-DX recur-
rence score that is a fixed combination of 21 gene expression assays. For
an observation with marker measurement Y = y and covariate value X = x,
let the standardized marker value be U = U(x, y) = P (Y > y|D = 0,X = x).
That is, using as a reference the marker distribution among controls with
covariate value x, U is the proportion of marker values in the reference dis-
tribution exceeding y. U has been called the placement value for Y [Pepe
and Cai (2004)] and 100 × (1 − U) is recognized as the percentile of Y
in the reference population [Hanley and Hajian-Tilaki (1997), Huang and
Pepe (2009a)]. Percentiles are commonly used to standardize growth and
lung function measurements for children and to standardize many labora-
tory measures. Note that the risk function can be written in terms of Y or U ,
P (D = 1|Y,X) = P (D = 1|U,X). Using the latter formulation, we propose
the following logistic regression model:
logitP (D = 1|U,X) = logitP (D = 1|X) +G(U,X,β),(2.1)
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where G(U,X,β) is some parametric function of U and X parameterized by
β, and logitP (D = 1|X) is an offset term that will be entered into the model
before the application of the logistic regression.
Interestingly, we can show that G(U,X,β) in this framework corresponds
to the log-derivative of ROCX , where ROCx is the ROC curve for Y in the
covariate specific population with X = x.
Theorem 1. Under model (2.1), ROCx(t) =
∫ t
0 exp{G(u,x,β)}du and
G(u,x,β) = logROC′x(u).
A proof of Theorem 1 can be found in Appendix A of the supplementary
material [Huang, Pepe and Feng (2013)]. The proposed framework (2.1)
therefore naturally links risk modeling with ROC analysis. These two ana-
lytic tasks are typically undertaken separately in current practice, leading
to disjointed and possibly inconsistent results, as illustrated in a simulated
example in Appendix B of the supplementary material [Huang, Pepe and
Feng (2013)]. Having a unified framework for risk modeling and for ROC
analysis offers a more coherent approach to biomarker evaluation.
2.2. Ensuring concave ROC curves. An important attribute of this frame-
work is that the ROC curve using the marker as the decision variable can
be easily constrained to be concave if desired. Concavity is a fundamental
characteristic of proper ROC curves [Egan (1975), Dorfman et al. (1996)].
In settings where it is reasonable to assume a monotone relationship be-
tween the risk of disease and the marker, the corresponding ROC curve for
the marker is necessarily concave. Yet concavity has not been strictly en-
forced in ROC modeling. Indeed, the classic binormal ROC model that is
widely used in radiology is not constrained to be concave. The binormal
ROC curve assumes the existence of a common monotone transformation
that transforms the marker distributions of cases and controls to normality,
but if the variances of those normal distributions differ, the ROC curve is
not concave. There have been several concave ROC models proposed in the
literature, including the “bigamma” ROC curve [Dorfman et al. (1996)], the
“bilomax” ROC curve [Campbell and Ratnaparkhi (1993)], and the “proper”
binormal ROC curve [Metz and Pan (1999)]. Use of these models has been
limited, however, partly due to difficulties in their implementation. In our
framework (2.1), we model G(u,x,β), the log-derivative of the ROC curve
directly rather than modeling the ROC curve itself. Consequently, it is easy
to constrain the ROC curve to be concave by modeling G(u,x,β) as a mono-
tone decreasing function of u.
2.3. Incorporating covariates. Equation (2.1) can be recognized as show-
ing the association between the pre-test and post-test risk of disease where
G(U,X,β) is known as the covariate specific diagnostic likelihood ratio. Us-
ing Bayesian terminology, G(U,X,β) is the Bayes factor that relates the
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prior and posterior probabilities of disease. However, very little methodol-
ogy exists that exploits its relationship with the ROC curve, G(U,X,β) =
logROC′X(U). To our knowledge, the only previous use of this framework is
by Gu and Pepe (2010), who exploited a simplified version of (2.1) without
covariates for a different problem of estimating the variance of the empirical
ROC curve in sample size calculation.
The framework provides a mechanism to incorporate covariates X into the
model for the ROC curve through G(U,X,β) = logROC′X(U). This model
provides opportunities for evaluating effects of covariates on the discrimina-
tory power of the marker. To illustrate, consider the following toy example.
Suppose X is comprised of two subsets X1 and X2 that can each be multi-
variate, for example, X1 = age and X2 = gender. Suppose we are interested
in testing whether X2 affects the marker’s classification accuracy. We model
G(U,X,β) as β0+β1r(U)+β
T
2 X1+β
T
3 X1r(U)+β
T
4 X2+β
T
5 X2r(U), where
r(u) is some pre-specified function of u. Then the null hypothesis H0, that
X2 does not affect the ROC curve, corresponds to zero coefficients for terms
involving X2, that is, H0 :β4 = β5 = 0. The approach applies in general: we
can test whether a subset of covariates affect the marker’s discriminatory
accuracy by testing the corresponding coefficients in the risk model. One
appealing property of (2.1) is that it naturally separates covariate effects for
marker standardization from covariate effects for ROC analysis. Specifically,
covariates used in deriving U are those affecting the marker distribution in
the control population, whereas covariates involved in G(U,X,β) are those
affecting the discriminatory power of the marker, as characterized by the
ROC curve.
Two natural competing methods existing in the literature for covariate
adjustment in ROC estimation using standardized marker values are the
nonparametric ROC adjustment method proposed by Janes and Pepe (2008,
2009) and various semiparametric regression methods based on the binormal
ROC model, such as the ROC-GLM method [Alonzo and Pepe (2002)] and
the pseudo-likelihood method [Pepe and Cai (2004)]. Compared to the non-
parametric method, applying a logistic regression form provides a much more
efficient alternative. As mentioned in Section 2.2, existing semiparametric
methods relying on the binormal ROC curve are not natural for modeling a
concave ROC curve. In addition, as detailed in Sections 3 and 4, they make
inference using standardized marker values among cases only, whereas the
proposed method utilizes standardized marker values for all subjects and
gains efficiency as a consequence.
2.4. Estimation. Consider first a cohort or cross-sectional study. Before
fitting the logistic regression model to estimate regression coefficients, we
first need to estimate the offset term logitP (D = 1|X) and the standardized
marker values U . Denote the estimators by Pˆ (D = 1|X) and Uˆ , respectively.
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For a cohort or cross-sectional study, Pˆ (D = 1|X) can be derived in stan-
dard fashion using logistic regression techniques or nonparametrically if X
is discrete. Computation of Uˆ requires estimating the distribution of Y in
the control population conditional on X . Methods have been described and
we refer to Huang and Pepe (2009a) for details. In particular, they suggest
nonparametric methods for discrete X , and parametric and semiparametric
methods for continuous X . After obtaining Pˆ (D = 1|X) and Uˆ , we substi-
tute them into the logistic regression model (2.1) to estimate coefficients
for X and Uˆ using standard logistic regression fitting procedures including
logit Pˆ (D = 1|X) as an offset term.
Consider a case–control sample where cases and controls are randomly
sampled from the case and control subpopulations. Estimation of U can be
performed as in a cohort or cross-sectional study. Let Sampled denote being
sampled into the case–control set. According to Bayes’ theorem, we have
P (D = 1|U,X)
P (D = 0|U,X
P (D = 0|X)
P (D = 1|X)
=
P (D = 1|U,X,Sampled)
P (D = 0|U,X,Sampled)
P (D = 0|X,Sampled)
P (D = 1|X,Sampled)
,
which implies that equation (2.1) can be written as
logitP (D = 1|U,X,Sampled)
= logitP (D = 1|X,Sampled) +G(U,X,β).
Thus, the estimate of regression coefficients for (2.1) can be obtained by
applying an ordinary logistic regression to D, X , and Uˆ to the case–control
sample with logit Pˆ (D = 1|X,Sampled) entered as an offset, where Pˆ (D =
1|X,Sampled) is an estimate of P (D = 1|X,Sampled) based on the case–
control sample.
After the model coefficients for (2.1) are obtained either based on a co-
hort, a cross-sectional, or a case–control sample, disease risk for each subject
can be computed by entering Pˆ (D = 1|X) and the individual’s Uˆ into the es-
timated model. For a case–control sample, in order to estimate P (D = 1|X),
information about prevalence, P (D = 1), has to be acquired externally, for
example, from the literature, from another independent cohort, or from the
parent cohort within which the case–control sample is nested. For evalua-
tion of a biomarker’s classification and prediction performance conditional
on covariates, methods have been developed previously when the risk of
disease conditional on the biomarker and covariates follows a logistic regres-
sion model [Huang, Pepe and Feng (2007), Huang and Pepe (2010a)]. These
methods can be applied here, replacing the biomarker value on the original
scale Y with their estimated standardized value Uˆ . Note that the Uˆ ’s are
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correlated with each other due to use of the control sample for estimating the
reference distributions for standardization. Hence, standard variance formu-
lae from logistic regression results do not apply, as they assume independence
between observations. Additional complexity is also introduced by using an
estimated offset term. Instead we propose bootstrap resampling for estimat-
ing variances of parameter estimators and constructing confidence intervals
using percentiles of the bootstrap distribution. The resampling procedures
need to mimic the design of the original study. Specifically, separate resam-
pling of cases and controls would be warranted if the study is of case–control
design, while for a cohort study resampling would be at random from the
cohort without regard to outcome status.
3. Methodology for combining data sources through a common ROC
curve.
3.1. Combining data sets with common ROC curves. In the remainder of
this manuscript, we focus on a specific problem where we evaluate biomarker
performance combining data from multiple sources through estimation of a
common ROC curve across data sources. The covariate X characterizes the
data source and we show how to use the logistic regression methodology to
take advantage of the constraint that the ROC curves are common across X .
The study motivating this research is a cross-sectional study conducted
by the Early Detection Research Network assessing a urine biomarker for
prostate cancer, Prostate Cancer Antigen 3 (PCA3). PCA3 is a prostate-
specific noncoding mRNA overexpressed in prostate tumors [Deras et al.
(2008)]. Among 576 men who were biopsied due to an elevated prostate spe-
cific antigen, half had had a previous (negative) biopsy and half had not
had a previous biopsy. Researchers were interested in assessing the risk pre-
diction and classification capacity of PCA3 in both populations, the initial
biopsy population and the repeat biopsy population. Interestingly, it was
observed that the empirical ROC curves for PCA3 were very similar in the
two populations [Figure 1(b)], even if it is well known that the initial biopsy
population has a higher prevalence of prostate cancer. This scenario raises
the question of how to combine data from the two populations in such a
way as to incorporate this common ROC condition when evaluating PCA3.
In this example, X = 0 indicates the initial biopsy population and X = 1
indicates the repeat biopsy population.
In general, let X denote the population and suppose that in prelimi-
nary analyses a test for equality of ROC curves across populations has
been accepted. The comparison between ROC curves in two populations
can be made through the comparison between distributions of case place-
ment values [Huang and Pepe (2009a)]. For example, comparison of the area
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under the ROC curve (AUC) between populations corresponds to compar-
ison of mean case placement values. Moreover, comparison can be made
with respect to the Wilcoxon Rank Sum statistic of case placement values
[Huang and Pepe (2009a)]. An alternative test may be based on fitting a
model of the form (2.1) and using a Wald test to determine if terms in-
volving X in G(U,X,β) can be eliminated. We next propose methods to
estimate the risk model, points on the ROC curve, ROCx(t), and the in-
verse of points on the predictiveness curve, CDFRx(p), where the predic-
tiveness curve is defined as the quantile curve of the disease risk [Bura and
Gastwirth (2001), Huang, Pepe and Feng (2007), Pepe et al. (2008)]. In
other words, the inverse of points on the predictiveness curve is the dis-
tribution of the disease risk, CDFRx(p) = P{Risk(X,Y )≤ p|X = x}, where
Risk(X,Y ) = P (D = 1|X,Y ). Without loss of generality, assume G(U,X,β)
in (2.1) can be modeled with β0 + β
T
1 r(U), a monotone decreasing function
of U , such that
logitP (D = 1|U,X) = logitP (D = 1|X) + β0 + β
T
1 r(U).(3.1)
Different prevalences and the common ROC curve are naturally and explic-
itly modeled in (3.1), with the ROC curve entirely determined by the coeffi-
cients of the risk model. None of the existing methods we are aware of can do
so. In particular, consider the standard method of fitting logistic regression
to the marker Y on its original scale and using the logit score to generate
the ROC curve in each population. Since the corresponding ROC curve de-
pends on both the risk model coefficients and the marker distribution in
each population, the common ROC assumption cannot be incorporated into
the logistic risk model without specifying the marker distributions.
3.2. Estimated empirical likelihood estimators. First, we consider an em-
pirical likelihood method. The key idea is to maximize the estimated em-
pirical likelihood of the observed Uˆ in the sample. The empirical likelihood
method has previously been used for evaluating goodness of fit for logistic re-
gression models and for constructing ROC curves based on raw marker mea-
sures only [Qin and Lawless (1994), Qin and Zhang (1997, 2003)]. Here we
extend it to accommodate additional covariates using standardized marker
values that are estimated.
Let FUDx and F
U
D¯x
denote the CDFs of U in the case and control popula-
tions, respectively, with covariate X = x. The logistic regression model (3.1)
implies an exponential tilt relationship between the probability densities of
U among cases and controls: dFUDx(u) = exp{G(u,x,β)}dF
U
D¯x
(u). Let ADx
and AD¯x be the set of cases and controls in the sample with X = x and
let nDx and nD¯x be the corresponding sample sizes. Let AD =
⋃
xADx and
AD¯ =
⋃
xAD¯x, let nD and nD¯ be the total number of cases and controls,
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and let n= nD+nD¯. With i indicating study subject, suppose we know the
true Ui, i= 1, . . . , n, the empirical likelihood given Ui is
L(β0, β1, F
U
D¯x
)
=
∏
x
∏
i∈A
D¯x
dFU
D¯x
(Ui)
∏
x
∏
i∈ADx
dFUDx(Ui)(3.2)
=
∏
x
∏
i∈A
D¯x
dFU
D¯x
(Ui)
∏
x
∏
i∈ADx
exp{β0 + β
T
1 r(Ui)}dF
U
D¯x
(Ui).
By definition, for controls the conditional distribution of U given X is
uniform(0,1). Moreover, for cases the conditional distribution of U given
X is the common ROC curve. Therefore, the distributions of U conditional
on disease status are the same across populations. Henceforth, we let pi and
exp{β0 + β
T
1 r(Ui)}pi be the “common” density of U for a control or a case
in the sample and the empirical likelihood (3.2) becomes{
n∏
i=1
pi
}[∏
x
∏
i∈ADx
exp{β0 + β
T
1 r(Ui)}
]
(3.3)
=
{
n∏
i=1
pi
}[ ∏
i∈AD
exp{β0 + β
T
1 r(Ui)}
]
,
subject to
∑n
i=1 pi = 1 and
∑n
i=1 exp{β0 + β
T
1 r(Ui)}pi = 1.
This empirical likelihood can be maximized using a Lagrange multiplier
approach by solving the equation
n∑
i=1
log(pi) +
∑
i∈AD
{β0 + β
T
1 r(Ui)} − λ1
n∑
i=1
(pi − 1)
− λ2
n∑
i=1
[exp{β0 + β
T
1 r(Ui)}pi− 1] = 0.
Consequently, (βˆ0, βˆ1), the maximum likelihood estimates of (β0, β1), satisfy
the following system of score equations:
∂l(β0, β1)
∂β0
= nD −
n∑
i=1
(nD/nD¯) exp{β0 + β
T
1 r(Ui)}
1 + (nD/nD¯) exp{β0 + β
T
1 r(Ui)}
= 0,
∂l(β0, β1)
∂β1
=
∑
i∈AD
r(Ui)−
n∑
i=1
r(Ui)(nD/nD¯) exp{β0 + β
T
1 r(Ui)}
1 + (nD/nD¯) exp{β0 + β
T
1 r(Ui)}
= 0,
which are the score equations for (β0, β1) if we apply a prospective logistic
model logit{P (D = 1|U)}= β0+β
T
1 r(U) to the data with offset nD/nD¯. The
maximum likelihood estimate of pi is pˆi = 1/[nD¯ + nD exp{βˆ0 + βˆ
T
1 r(Ui)}].
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In practice, we substitute Uˆi for Ui into the empirical likelihood (3.2) to
get an estimated empirical likelihood, and obtain βˆ0 and βˆ1 with a logis-
tic regression model based on Uˆi. The corresponding estimated empirical
likelihood estimators of FU
D¯x
and FUDx are
FˆU
D¯x
(u) =
1
nD¯
n∑
i=1
I(Uˆi ≤ u)
1 + (nD/nD¯) exp{βˆ0 + βˆ
T
1 r(Uˆi)}
,
FˆUDx(u) =
1
nD¯
n∑
i=1
exp{βˆ0 + βˆ
T
1 r(Uˆi)}I(Uˆi ≤ u)
1 + (nD/nD¯) exp{βˆ0 + βˆ
T
1 r(Uˆi)}
,
which is the same across X levels. Note this procedure can be applied
whether or not there are tied values of Uˆi in the sample.
A piecewise differentiable and concave estimator of the common ROC
curve R̂OCx(t) = R̂OC(t) = Fˆ
U
DxFˆ
U−1
D¯x
(t) can be constructed based on FˆUDx
and FˆU
D¯x
using methods analogous to those proposed by Qin and Zhang
(2003), Huang (2007) and Huang and Pepe (2009c). The procedure is out-
lined in Appendix C of the supplementary material [Huang, Pepe and Feng
(2013)]. Finally, we estimate FUx , the distribution of U conditional on covari-
ate X = x with FˆUx (u) = Pˆ (D = 0|X = x)Fˆ
U
D¯x
(u) + Pˆ (D = 1|X = x)FˆUDx(u),
and estimate disease risk conditional on Uˆ and X by substituting βˆ0 and βˆ1
into (3.1). Then for a particular risk threshold p, we estimate CDFRx(p), the
risk distribution at X = x, with 1− FˆUx {u(p,x)}, the proportion of subjects
with covariate x that have Uˆ larger than u(p,x) = supi∈{1,...,n}{Uˆi : Pˆ (D =
1|Uˆ ,X = x) ≥ p}. We call estimators obtained using the approach in this
section the “estimated empirical likelihood estimators” (EML).
3.3. Constrained estimated maximum likelihood estimators. The estimat-
ed empirical likelihood method proposed in Section 3.2 is easy to implement
using standard statistical software. In this method, the relationship between
the ROC curve and the logistic regression model presented in Theorem 1 is
utilized for combining Uˆ across different covariate levels to estimate a com-
mon distribution as in (3.3), under a common ROC assumption. Based on a
discrete support for Uˆ , the corresponding ROC curve estimate is piecewise
differentiable. As we will show next, an alternative way to exploit the rela-
tionship in Theorem 1 is to use it as a constraint directly when estimating
parameters in the risk model. Since the ROC curve is completely specified
by the coefficients in the logistic regression model (3.1), this procedure leads
to a smooth ROC curve estimate.
Observe that G(t, x, β) = logROC′x(t) implies that the common ROC(t)
is equal to
∫ t
0 exp{G(u,x,β)}du, which is independent of x and can be es-
timated by replacing β with a consistent estimate based on the logistic
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regression model (3.1). Unlike the typical logistic regression model where
there is no constraint on the parameter space, however, the risk model (3.1)
based on the standardized marker has an implicit constraint: ROC(1) =∫ 1
0 exp{β0 + β
T
1 r(t)}dt = 1 by definition of the ROC curve. The standard
log-likelihood for D conditional on U and X based on the logistic model is
l=
n∑
i=1
Di log{P (Di = 1|Ui,Xi)}+ (1−Di) log{1−P (Di = 1|Ui,Xi)}.(3.4)
We propose to maximize the estimated version of this log-likelihood (3.4)
by substituting Uˆ for U , with the additional constraint that
∫ 1
0 exp{β0 +
βT1 r(t)}dt= 1.
The method used to enforce this constraint in the estimation procedure
depends on the complexity of β1. For example, for a univariate β1, β0 can be
represented by a closed-form function of β1 :β0 = log[β1/{exp(β1)− 1}] as
ROC(1) = {exp(β0 + β1)− exp(β0)}/β1 = 1. For more complicated models,
numerical methods are needed to represent β0 as a function of β1. Let (βˆ0, βˆ1)
be the estimate of β that maximizes the constrained estimated maximum
likelihood. We estimate the common ROC curve with R̂OCx(t) = R̂OC(t) =∫ t
0 exp{βˆ0 + βˆ
T
1 r(u)}du.
The CDF of risk conditional on X = x can be derived from R̂OCx and the
disease prevalence estimate Pˆ (D = 1|X = x) by exploiting the relationship
between the ROC curve and the risk distribution shown in Huang and Pepe
(2009b). Specifically, for p ∈ (0,1), CDFRx(p) can be estimated by 1−{1−
Pˆ (D = 1|X = x)}t− Pˆ (D = 1|X = x)R̂OCx(t), where t satisfies
Pˆ (D = 1|X = x)R̂OC′x(t)/{Pˆ (D = 1|X = x)R̂OC
′
x(t) + 1− Pˆ (D = 1|X = x)}
= p.
We call estimators obtained using the methods in this section the “con-
strained estimated maximum likelihood estimators” (CML).
3.4. Connection to and modification of existing methods. Our approach
to fitting a common ROC curve across populations is similar in spirit to the
covariate-adjusted ROC curve proposed by Janes and Pepe (2008, 2009),
which is defined as a weighted average of covariate-specific ROC curves
AROC(t) =
∫
ROCx(t)dFD(x), where FD(x) is the CDF of X among dis-
eased case subjects. When ROCx is the same for different values of x, AROC
is the common ROC curve. Janes and Pepe (2008, 2009) proposed estimating
AROC nonparametrically using the empirical CDF of Uˆ for all cases, where
Uˆi =
∑n
D¯Xi
j=1 I(Yi > Yj)/nD¯Xi , exploiting the fact that the distribution of U
for diseased observations is equal to the ROC curve. Alternatively, semi-
parametric methods can be used to model the distribution of U , that is, the
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common ROC curve. One choice of semiparametric estimator is the pseudo-
likelihood estimator (PSL), originally proposed by Pepe and Cai (2004) for
estimating the ROC curve in a single population. In Pepe and Cai (2004),
the PSL method imposes a parametric functional form on the ROC curve
such as a binormal form, and maximizes the likelihood of Uˆ among diseased
case subjects. This approach is easy to implement and has been shown to
have good efficiency compared to other semiparametric ROC modeling ap-
proaches. Here we modify the PSL method by modeling the derivative of
the ROC curve directly, thereby accommodating the model form implied by
the logistic regression framework (3.1). Specifically, we maximize
l=
∑
i∈AD
log dFUDx(Uˆi) =
∑
i∈AD
logROC′x(Uˆi) =
∑
i∈AD
{β0 + β
T
1 r(Uˆi)}.
In addition, we enforce the constraint ROC(1) = 1 as in the CML method.
Since the PSL method uses only the standardized marker value in dis-
eased observations, we expect that some efficiency could be gained from
our method by including standardized marker values for nondiseased con-
trol observations as well.
4. Application to simulated data. To mimic the setting in the PCA3
example, we simulated random samples from two populations with disease
prevalences equal to 0.44 and 0.27, respectively. Marker distributions for
controls are N(0,1) in population 1 and N(1,1) in population 2. Marker
distributions for cases from each population are chosen to achieve a com-
mon ROC curve with ROC′(t) = exp(β0 + β1t+ β2t
2). With X being the
population indicator variable, X = 1 for population 2, the risk model is
logitP (D = 1|U,X) = α0 +α1X + β0 + β1U + β2U
2,(4.1)
where the offset terms α0 and α0 + α1 are log odds of the prevalences in
the two populations, which will be estimated empirically from the sample
and entered into the model before estimation of the other parameters in the
logistic regression model.
We generated 300 observations from each population (cf. Section 5: the
PCA3 data set has 267 men in each population). We compared the CML,
EML, and PSL estimators for estimating: (i) β = (β0, β1, β2); (ii) ROC(t)
for t= 0.1,0.3,0.5,0.7,0.9; (iii) the risk distribution, CDFRx(p) versus p in
each population for p equal to 10%, 30%, 50%, 70%, and 90%; and (iv)
Risk(y|x) = P (D = 1|Y = y,X = x) in each population, for y corresponding
to p in (iii). In each simulation, the standardized marker value U ’s are esti-
mated based on nonparametric CDF estimates of the control distribution in
each population. For each estimator, we used both the population-specific
approach where only samples from the target population are used for es-
timation and the combined-data approach where we estimate a common
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ROC curve across populations. We performed 10,000 Monte Carlo simula-
tions with 500 bootstrap samples for each simulated data set to construct
confidence intervals
All three estimators, EML, CML, and PSL, have negligible bias (Table 1).
Moreover, coverage of their 95% bootstrap percentile confidence intervals are
all close to the nominal level (Table 2). We note that for a sample of size
300 in each population, an alternative to percentile bootstrap confidence
intervals are Wald confidence intervals with a bootstrap standard error es-
timate, which can achieve reasonable coverage with a smaller bootstrap size
such as 50; yet for smaller sample sizes (e.g., 100 in each population), they
tend to have an under-coverage problem (details omitted). We recommend
percentile bootstrap confidence intervals for our estimators in general, as
they have better performance overall.
Table 3 shows the efficiencies of the three estimators relative to each other.
We use the population-specific CML estimator as the reference in this table
so the entries are the variances of the CML estimator that employs data
for the target population only relative to variances of the estimators. In
general, the EML estimator appears to be slightly less efficient than the
CML estimator, and both the CML and EML estimators are slightly more
efficient than the PSL estimator. Most importantly, Table 3 shows that the
combined-data analysis dramatically increases efficiency compared to using
only the population-specific data. The magnitude of the efficiency gain varies
with the measures and the target population of interest. For example, when
population 1 is the target population, the relative efficiency of the combined-
data analysis versus the population-specific method ranges from 1.6–1.8 for
ROC estimation, and ranges from 1.1–1.4 for risk distribution estimation;
when population 2 is the target population, the relative efficiency of the
combined-data analysis versus the population-specific method ranges from
2.2–2.4 for ROC estimation, and ranges from 1.3–1.5 for risk distribution
estimation.
Since the nonparametric method is commonly used for estimating ROC
and AROC curves, we compared their performances with the proposed
method based on the logistic regression framework. In Table 4 we present
the nonparametric estimate of the ROC curve within each population and
the nonparametric AROC estimate that combines data from the two pop-
ulations to estimate the common ROC curve. While the nonparametric es-
timates have minimal bias, it appears in our simulation setting that cover-
age of the bootstrap percentile confidence interval can be remarkably below
nominal levels for points at the end of the ROC curve. Moreover, we see
that the logistic regression framework gains substantial efficiency over the
nonparametric method. The efficiency of the CML estimator relative to the
nonparametric estimator varies from 1.2 to 1.9 in Table 4.
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Table 1
Bias of different estimators (multiplied by 1000 and rounded) using data from the target population or based on the combined-data
analysis. EML is the estimated empirical likelihood estimator, CML is the constrained estimated maximum likelihood estimator, PSL is
the constrained pseudolikelihood estimator. Standard errors of biases are less than 0.03 for β estimates, less than 0.001 for estimates of
ROC(t) and Risk(y|x), and less than 0.002 for estimates of CDFRx(p)
Population 1 Population 2
Population-specific Combined-data analysis Population-specific Combined-data analysis
EML CML PSL EML CML PSL EML CML PSL EML CML PSL
True Bias×1000 True Bias×1000
β
β0 −4 13 2 −6 22 13 3 −4 10 2 −8 22 13 3
β1 1 −73 −52 −30 −120 −107 −72 1 −54 −41 0 −120 −107 −72
β2 2 14 −1 5 85 75 66 2 −36 −45 −65 85 75 66
ROC(t)
t= 0.1 0.27 5.9 4.2 2.5 5.9 4.5 2.5 0.27 5.8 5.1 3.0 5.9 4.5 2.5
t= 0.3 0.59 3.6 2.8 −0.1 4.1 3.8 0.6 0.59 4.3 4.0 1.2 4.1 3.8 0.6
t= 0.5 0.77 1.6 1.5 −1.0 1.6 1.8 −0.7 0.77 2.6 2.7 0.6 1.6 1.8 −0.7
t= 0.7 0.89 −0.1 0.0 −1.6 −0.2 0.0 −1.6 0.89 0.3 0.5 −0.8 −0.2 0.0 −1.6
t= 0.9 0.97 −1.0 −1.0 −1.6 −0.8 −0.7 −1.3 0.97 −1.2 −1.2 −1.6 −0.8 −0.7 −1.3
CDFRx(p)
p= (0.22,0.12)⋆ 0.10 7.3 7.6 3.8 0.8 1.4 −3.3 0.10 22.2 22.8 18.9 10.4 10.9 5.9
p= (0.30,0.16) 0.30 −1.2 −1.7 −4.5 3.1 3.0 −0.1 0.30 −10.6 −10.3 −15.0 −1.7 −1.6 −6.4
p= (0.43,0.23) 0.50 −1.0 −2.4 −2.1 2.3 1.2 1.3 0.50 0.6 −0.3 −1.2 4.5 3.4 2.6
p= (0.56,0.35) 0.70 4.0 3.4 5.9 2.2 1.3 3.8 0.70 0.9 0.4 1.3 2.5 1.3 2.7
p= (0.67,0.48) 0.90 −4.2 −1.7 1.3 −4.7 −3.1 0.7 0.90 0.4 1.2 3.7 −1.0 0.1 3.1
Risk(y|x)
y = (−1.1,−0.2)⋆ 0.22 −1.3 −2.0 0.4 −0.2 −1.1 1.3 0.12 −0.6 −1.0 0.2 0.5 0.0 1.5
y = (−0.24,−0.64) 0.31 −2.2 −3.0 −1.5 −2.2 −3.2 −1.4 0.16 −2.6 −3.1 −2.0 −1.4 −2.0 −0.8
y = (0.33,1.20) 0.43 0.1 −1.3 −1.2 −1.0 −2.4 −1.8 0.24 −0.7 −1.5 −0.7 −1.1 −2.0 −1.4
y = (0.88,1.75) 0.56 3.0 1.1 0.5 1.7 −0.3 −0.5 0.35 2.6 1.2 1.0 0.9 −0.3 −1.0
y = (1.6,2.5) 0.67 1.7 −0.5 −1.4 2.7 0.8 −0.4 0.48 3.2 1.4 0.2 3.4 1.6 −0.2
⋆: the values separated by commas correspond to population 1 and population 2, respectively.
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Table 2
Coverage of 95% percentile bootstrap confidence intervals (subtracted by 95.0 and then multiplied by 10), based on the estimated
empirical likelihood estimator (EML), the constrained estimated maximum likelihood estimator (CML), and the pseudo likelihood
estimator (PSL) using data only from the target population or based on the combined-data analysis. Standard errors of entries do not
exceed 0.4% of the value
Population 1 Population 2
Population-specific Combined-data Population-specific Combined-data
EML CML PSL EML CML PSL EML CML PSL EML CML PSL
β
β0 =−3.8 −10 −6 −4 −17 −8 −2 −9 −8 −3 −17 −8 −2
β1 = 1.2 −5 −5 −8 −8 −6 0 −7 −8 −2 −8 −6 0
β2 = 1.5 −5 −4 −5 −5 −1 −2 −7 −7 −4 −5 −1 −2
ROC(t)
t= 0.1 −7 −5 −3 −16 −10 −1 −11 −6 −5 −16 −10 −1
t= 0.3 −8 −8 −4 −13 −14 −10 −9 −8 −6 −13 −14 −10
t= 0.5 −8 −7 −2 −10 −11 −6 −14 −13 −9 −10 −11 −6
t= 0.7 −7 −8 −3 −5 −6 −4 −12 −15 −9 −5 −6 −4
t= 0.9 −5 −6 −4 −5 −6 −5 −13 −14 −11 −5 −6 −5
CDFRx(p)
p= (0.22,0.12)⋆ −2 −4 1 −1 −1 5 −20 −21 −14 −4 −8 −1
p= (0.30,0.16) 2 1 1 0 −3 2 −4 −7 −5 3 1 5
p= (0.43,0.23) −1 −3 −4 −2 −3 −3 8 5 6 1 4 2
p= (0.56,0.35) −1 −6 −4 −3 −8 −7 8 5 4 2 0 −2
p= (0.67,0.48) −11 −8 −6 −7 −7 −3 −5 −6 −3 −5 −4 −4
Risk(y|x)
y = (−1.1,−0.17)⋆ −4 −6 0 0 −1 2 −19 −21 −15 −4 −7 −5
y = (−0.24,0.64) −2 −5 −3 −2 −7 0 −10 −12 −6 3 0 5
y = (0.33,1.2) −5 −4 −2 1 −2 1 1 1 0 0 0 1
y = (0.88,1.7) −5 −1 −1 −2 0 −1 5 6 6 4 3 3
y = (1.6,2.5) −16 −12 −10 −14 −8 −5 −6 −3 −1 −2 0 2
⋆: the values separated by commas correspond to population 1 and population 2, respectively.
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Table 3
Efficiency of other estimators (using data from the target population or based on the
combined-data analysis) relative to the constrained maximum likelihood estimator
calculated using data only from the target population. Standard errors of entries do not
exceed 3% of the value
Population 1 Population 2
Pop-specific Combined-data Pop-specific Combined-data
EML PSL EML CML PSL EML PSL EML CML PSL
β
β0 =−3.8 0.98 0.94 1.81 1.89 1.77 0.98 1.00 2.24 2.34 2.20
β1 = 1.2 0.99 0.92 1.81 1.87 1.73 0.99 0.99 2.27 2.35 2.18
β2 = 1.5 0.99 0.91 1.80 1.85 1.70 0.99 0.98 2.35 2.42 2.23
ROC(t)
t= 0.1 0.96 0.95 1.75 1.84 1.76 0.99 1.01 2.16 2.28 2.18
t= 0.3 0.99 0.98 1.77 1.81 1.77 1.00 1.01 2.25 2.31 2.25
t= 0.5 0.99 0.98 1.71 1.75 1.71 0.99 0.99 2.33 2.38 2.33
t= 0.7 0.98 0.95 1.66 1.71 1.62 0.98 0.97 2.33 2.39 2.27
t= 0.9 0.97 0.92 1.66 1.72 1.59 0.98 0.96 2.31 2.39 2.21
CDFRx(p)
p= (0.22,0.12)⋆ 0.99 1.01 1.14 1.15 1.17 1.00 1.02 1.28 1.29 1.32
p= (0.30,0.16) 0.98 0.95 1.31 1.35 1.26 0.99 0.97 1.39 1.43 1.36
p= (0.43,0.23) 0.96 0.96 1.20 1.24 1.19 0.99 0.98 1.35 1.40 1.34
p= (0.56,0.35) 0.98 0.96 1.37 1.38 1.35 0.99 0.98 1.44 1.46 1.42
p= (0.67,0.48) 0.98 1.00 1.24 1.25 1.25 0.99 1.01 1.26 1.28 1.26
Risk(y|x)
y = (−1.1,−1.2)⋆ 1.00 0.96 1.51 1.53 1.47 0.99 0.97 1.98 2.00 1.91
y = (−0.24,−0.36) 0.99 0.95 1.32 1.32 1.29 1.00 1.00 1.51 1.55 1.49
y = (0.33,0.20) 0.99 0.92 1.16 1.14 1.13 0.99 0.98 1.35 1.40 1.32
y = (0.88,0.75) 1.00 0.99 1.08 1.08 1.08 0.99 1.00 1.10 1.12 1.10
y = (1.6,1.5) 1.00 0.93 1.40 1.45 1.34 0.99 0.98 1.53 1.53 1.50
⋆: the values separated by commas correspond to population 1 and population 2, respec-
tively.
We further evaluated the proposed methods by varying the simulation
settings. Results for estimating the ROC curve, risk, and risk distribution
are presented in Appendix D of the supplementary material [Huang, Pepe
and Feng (2013)]. We examined two additional scenarios where the com-
mon ROC curve condition holds across two populations. The first scenario
has smaller sample sizes (100 in each populations) compared to the primary
setting (Tables 1–3 in Appendix D). The second scenario has different con-
trol marker distributions across populations [N(0,1) in population 1 and
logNormal(1,1) in population 2] (Tables 4–6 in Appendix D). Smaller sam-
ple sizes lead to slightly larger bias. But overall we observe minimal bias,
good coverage, and good efficiency gain with the combined-data analysis in
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Table 4
Performance of the nonparametric ROC(t) and AROC(t) estimators. Standard errors of
biases of ROC(t) or AROC(t) are less than 0.001. Standard errors for coverage of 95%
confidence intervals do not exceed 0.7% of the value. Standard errors for relative
efficiency do not exceed 1% of the value
Population 1 Population 2 Combined-data
Bias×1000
t= 0.1 0.012 0.014 0.008
t= 0.3 0.005 0.008 0.002
t= 0.5 0.004 0.006 0.002
t= 0.7 0.004 0.006 0.002
t= 0.9 0.004 0.006 0.002
Coverage of 95% bootstrap percentile CI
t= 0.1 94.4 95.4 95.6
t= 0.3 95.4 94.6 95.7
t= 0.5 94.8 94.2 95.6
t= 0.7 94.0 92.4 95.3
t= 0.9 90.2 82.9 93.8
Efficiency of CML relative to the nonparametric estimator
t= 0.1 1.83 1.64 1.84
t= 0.3 1.21 1.23 1.26
t= 0.5 1.28 1.29 1.32
t= 0.7 1.22 1.23 1.25
t= 0.9 1.72 1.68 1.88
each of the two scenarios. We also examined another scenario where there is
a slight difference in the ROC curves between the two populations, with the
area under the ROC curve 5% larger in population 2 relative to population
1. In the presence of a small difference in ROC curves, the combined-data
approach estimating the common ROC curve has slightly larger bias com-
pared to the population-specific approach, but in general still maintains a
good efficiency gain in terms of an appreciable drop in the mean squared
error (Tables 7–8 in Appendix D).
5. Application to a prostate cancer data set. We illustrate our method-
ology using the PCA3 example data set that includes 576 patients [Deras
et al. (2008)] who underwent a diagnostic biopsy for prostate cancer due
to elevated PSA levels. Among these subjects, 267 had a previous negative
biopsy and 267 subjects had no previous biopsy.
Figure 1(a) shows probability density functions for log(PCA3) conditional
on disease status, and Figure 1(b) shows the empirical ROC curves in the
two populations. Interestingly, although the distributions of PCA3 condi-
tional on disease status seem to differ between the two populations, the two
ROC curves appear similar to each other. A test for equality of the ROC
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Fig. 1. (a) density of log(PCA3) conditional on disease status in each population; (b)
nonparametric and (c) semiparametric ROC curves for PCA3 in initial and repeat biopsy
populations, and the common ROC curve adjusting for population effect.
curves based on the area under the ROC curves yields a p-value of 0.66. An
alternative test comparing case placement values using the Wilcoxon Rank
Sum statistic yields a p-value of 0.45 [Huang and Pepe (2009a)]. Also pre-
sented in Figure 1(b) is the nonparametric estimate of the common ROC
curve [Janes and Pepe (2009)] ÂROC(t) =
∑nD
i=1 I{YDi > Sˆ
−1
D¯Xi
(t)}/nD .
As we have noted earlier, we cannot enforce a common ROC condition
by fitting a logistic model with Y on the usual scale. But fitting a model
with Y on the U scale such as logitP (D = 1|U,X) = logitP (D = 1|X) +
β0+β
T
1 r(U) automatically guarantees a common ROC across X . We adopt
a logistic model logitP (D = 1|U,X) = logitP (D = 1|X) +β0+ β1U + β2U
2.
Figure 1(c) displays the ROC curve estimates calculated by fitting this model
separately in the two populations and by using the combined-data analysis
method. Observe that the curves are all concave and are very similar to each
other. However, the combined-data analysis estimates are much more precise
(Table 5). Borrowing information across populations leads to an efficiency
gain of over 50% compared to using the initial biopsy sample only and
over 100% gain in efficiency compared to using the repeat biopsy sample
only. Comparing the CML estimates of the common ROC(t) (combined-
data analysis) with the nonparametric AROC(t) estimates [Figure 1(b)],
the efficiency gains through modeling the ROC derivative are 87%, 41%,
78%, 51%, and 74%, respectively, for t= 0.1,0.3,0.5,0.7, and 0.9.
The estimated risk is shown in Figure 2 as a function of log(PCA3) and the
risk distributions in the two populations are shown as well. Again, curves
derived from fitting the risk model to each population separately appear
to be similar to those derived from the combined-data analysis. Urologists
are particularly interested in the capacity of PCA3 to identify high risk
subjects from the initial biopsy population and low risk subjects from the
repeat biopsy population. Toward this goal, we want to have an accurate
L
O
G
IS
T
IC
R
E
G
R
E
S
S
IO
N
A
N
A
L
Y
S
IS
W
IT
H
S
T
A
N
D
A
R
D
IZ
E
D
M
A
R
K
E
R
S
1
9
Table 5
The constrained maximum likelihood estimators calculated with data from the PCA3 study
Initial biopsy Repeat biopsy
Combined-data Population specific Combined-data Population specific
ROC(t)
t= 0.1 Est 0.266 (0.209, 0.339) 0.274 (0.205, 0.368) 0.266 (0.209, 0.339) 0.256 (0.166, 0.369)
Eff⋆ 1.57 1.00 2.53 1.00
t= 0.3 Est 0.591 (0.518, 0.671) 0.600 (0.510, 0.704) 0.591 (0.518, 0.671) 0.578 (0.462, 0.697)
Eff 1.57 1.00 2.41 1.00
t= 0.5 Est 0.772 (0.710, 0.831) 0.778 (0.703, 0.854) 0.772 (0.710, 0.831) 0.764 (0.670, 0.847)
Eff 1.64 1.00 2.21 1.00
t= 0.7 Est 0.886 (0.836, 0.927) 0.889 (0.827, 0.939) 0.886 (0.836, 0.927) 0.882 (0.810, 0.940)
Eff 1.67 1.00 2.19 1.00
t= 0.9 Est 0.967 (0.943, 0.982) 0.967 (0.937, 0.986) 0.967 (0.943, 0.982) 0.966 (0.930, 0.987)
Eff 1.67 1.00 2.32 1.00
CDFR(p) p= 0.65 p= 0.20
Est 0.855 (0.711, 1.000) 0.843 (0.698, 1.000) 0.418 (0.276, 0.564) 0.406 (0.211, 0.586)
Eff 1.12 1.00 1.60 1.00
Risk(y) y = 60 y = 20
Est 0.654 (0.567, 0.731) 0.659 (0.569, 0.749) 0.208 (0.147, 0.270) 0.214 (0.135, 0.292)
Eff 1.22 1.00 1.59 1.00
Eff⋆: efficiency relative to the population-specific estimator.
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Fig. 2. Risk as a function of log(PCA3) and versus the CDF of Risk in the (a) initial
biopsy and (b) repeat biopsy populations.
prediction of the prostate cancer risk as a function of PCA3 among each pop-
ulation, and to have a good assessment of the population impact of PCA3
in assisting treatment decision. Here we evaluate the risk of prostate can-
cer at PCA3 = 60, denoted by Risk(60), for the former population and the
risk of prostate cancer at PCA3 = 20, denoted by Risk(20), for the latter
population. In addition, suppose an estimated risk greater than 0.65 will
lead to a recommendation for treatment and a risk below 0.20 will lead to
a recommendation against treatment. Therefore, we assess CDFR(0.65) in
the initial biopsy population and CDFR(0.20) in the repeat biopsy popu-
lation. Table 5 presents the CML estimators for those quantities based on
population-specific analysis and on combined-data analysis. Again, both ap-
proaches result in similar estimates, but combined-data analysis yields more
precise estimates. The efficiency of the combined-data analysis is modest for
evaluating the risk prediction capacity of PCA3 in the initial biopsy pop-
ulation [1.22 for estimating Risk(60) and 1.12 for estimating CDFR(0.65)],
but much larger when the repeat biopsy population is concerned, around 1.6
for both Risk(20) and CDFR(0.20). Our results provide useful information
to urologists regarding the value of PCA3 in treatment decision making. In
particular, based on a high risk threshold of 0.65 and a low risk threshold of
0.20, use of PCA3 will recommend 86% of subjects for treatment in initial
biopsy population and will spare 58% of subjects from treatment in repeat
biopsy population.
6. Discussion. In this paper we proposed a logistic regression framework
for modeling marker values after they are standardized using the distribution
in the nondiseased control population. This sort of standardization is often
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used in laboratory and clinical medicine. For example, Frischancho (1990)
provides weight and height of children standardized relative to a healthy
population of children of the same age and gender. Our framework provides
a convenient way to connect risk modeling with ROC analysis with many
applications. For example, one can use it for simply estimating the ROC
curve from a single cohort or case–control study, for evaluating covariate
effects on biomarker performance, and for combining data sources in eval-
uating biomarker performance through the estimation of a common ROC
curve when applicable, as presented in this paper.
Covariate adjustment is an important issue in ROC curve evaluation.
When a biomarker’s distribution depends on covariates, adjusting for the co-
variate effect allows an evaluation of biomarker’s classification performance
independent of the covariate level. Estimation of a common ROC curve ad-
justing for a covariate that affects marker distribution in a classification
study is analogous to estimation of a common odds ratio across covariate
strata in an association study but requires different techniques for covari-
ate adjustment. While the covariates to be adjusted for in odds ratio esti-
mation are included in the regression model, covariate-adjustment in ROC
analysis is achieved in the step of marker standardization. We developed
two types of combined-data analysis estimators based on a common ROC
curve. The constrained estimated maximum likelihood estimator is more
efficient when there is large variability in estimated standardized marker
values across populations, due, for example, to variation in the sizes of the
reference nondiseased sample across populations. The estimated empirical
likelihood estimator, on the other hand, is easier to implement and may be
preferable for complicated models. R code for computing the two estimators
is available upon request. An easy-to-implement nonparametric method for
covariate-adjustment in ROC estimation has been proposed in Janes and
Pepe (2008, 2009). Our logistic regression based estimator provides a much
more efficient semiparametric alternative. An additional advantage of our
semiparametric method over the nonparametric method is the ease of re-
trieving the ROC derivative, which can be used for various purposes, in-
cluding the derivation of the risk distribution [Huang and Pepe (2009b)].
Moreover, while the nonparametric method does not model risk factors for
risk prediction and operationally is more suitable for discrete X , our frame-
work has the same flexibility as a traditional logistic regression model. Our
method also provides a useful addition to the semiparmatric ROC modeling
field. Unlike other existing semiparametric ROC regression methods [e.g.,
by Pepe and Cai (2004), Alonzo and Pepe (2002), Dodd and Pepe (2003)]
that posit assumptions on the functional form of the ROC curve (typically
a binormal ROC form), we fit a model to the ROC derivative directly. One
attractive property of this strategy is that one can easily build in the con-
straint that the ROC curve is concave, which is a fundamental attribute
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of proper ROC curves, whereas the traditional binormal ROC model is not
natural for ensuring concavity. Another attractive feature of the logistic re-
gression framework is that it accommodates case–control sampling which is
common in biomarker research studies [Pepe et al. (2001)].
Moreover, as shown in Sections 3.4 and 4, another novelty of the logistic
regression framework over existing ROC regression methods based on marker
standardization is the way the standardized marker values are used. Our
approach fits a prospective risk model based on standardized marker values
among all subjects and is more efficient compared to the traditional ROC
regression methods that build on standardized marker value among cases
only.
Our methods for combining data from different sources is flexible and
applies whether or not the components combined have the same study de-
sign. For example, we can have one component being a case–control study
and the other component a cohort study. Frequency matching in case–
control studies can also be accommodated by adjusting for biased sampling
in estimation of the standardized marker value and in fitting of the lo-
gistic regression model. The former can be conducted using the fact that
U(y) = P (Y > y|D = 0) =
∑
sP (Y > y|D = 0, S = s)P (D = 0|S = s) for
cases and controls frequency-matched within stratum S. The latter can be
conducted weighting the contribution of each observation to the likelihood
by the inverse of the sampling probability.
Finally, we want to point out that there are different ways to assess our
model calibrations in practice. The direct correspondence between our risk
model and the ROC model allows assessment of model calibration based on
ROC model checking techniques such as those proposed in Cai and Zheng
(2007). In our motivating example, goodness of fit can be demonstrated
graphically comparing the nonparametric estimate of the covariate-adjusted
ROC curve with our semiparametric estimates. Alternatively, model check-
ing can be conducted through general Hosmer–Lemeshow type techniques
developed for logistic regression [Hosmer and Lemeshow (1980), Huang and
Pepe (2010b)].
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SUPPLEMENTARY MATERIAL
Supplementary Appendix (DOI: 10.1214/13-AOAS634SUPP; .pdf). Sup-
plement: Proof of Theorem 1, a simulated example referred to in Section 2.1,
steps of the construction of a concave ROC curve based on the pseudoem-
pirical likelihood estimators, and additional simulation results. The supple-
mentary material would be provided at this location.
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